Skip to main content

Table 1 Patient characteristics at inclusion

From: Phytalgic®, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial

  Phytalgic® Placebo
Total number of subjects 41 40
Male/female 14/27 12/28
Mean Age (range), years 56.8 (28 to 79) 57.5 (28 to 84)
Osteoarthritis (n)   
   One knee 13 21
   Two knees 12 8
   One hip 8 5
   Two hips 3 4
   Knees and hips 5 2
WOMAC scores at inclusion
(mean ± SD)
  
   Pain score 215.7 ± 88.0 229.5 ± 112.1
   Stiffness score 98.6 ± 50.6 97.9 ± 63.2
   Function score** 688.8 ± 281.0 689.0 ± 368.9
   Total score** 1000.8 ± 391.5 1014.6 ± 526.8
Ongoing treatment (n)   
Analgesics (number of users, tablets/week ± SD) 34 (19.8 ± 12.7) 35 (19.1 ± 14.4)
   Single-component Paracetamol 12 (21 ± 14.7) 15 (15.4 ± 10.4)
   Combined Paracetamol 19 (15.6 ± 10.9) 17 (15.1 ± 12.1)
NSAIDs: n (DDD ± SD) 23 (1.3 ± 0.9) 23 (1.1 ± 1.1)
OA Treatment*: n (DDD ± SD) 16 (1.1 ± 0.5) 12 (0.9 ± 0.4)
  1. *OA treatment: slow-acting drugs such as diacerhein, glucosamine, chondroitin sulphate...
  2. DDD: defined daily doses; WOMAC: Western Ontario-Macmaster University Osteoarthritis scores;
  3. **Four patients with missing scores at baseline (two patients in each group)
  4. Values are numbers of patients, or mean value ± SD unless otherwise indicated. There was no significant difference between the randomized study groups.